 Doug Madison on Aug 17th, 2018 // No Comments
vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman bought 570,777 shares of the firm's stock in a transaction that occurred on Friday, August 10th. The shares were acquired at an average price of $4.38 per share, with a total value of $2,500,003.26. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website . Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
VTVT stock opened at $1.10 on Friday. The company has a market cap of $43.51 million, a P/E ratio of -0.66 and a beta of 1.67. vTv Therapeutics Inc has a fifty-two week low of $0.65 and a fifty-two week high of $8.40. The company has a debt-to-equity ratio of -0.15, a current ratio of 0.19 and a quick ratio of 0.19. Get vTv Therapeutics alerts:
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Friday, August 3rd. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The company had revenue of $2.47 million during the quarter, compared to analysts' expectations of $2.46 million. sell-side analysts anticipate that vTv Therapeutics Inc will post -0.87 earnings per share for the current fiscal year. Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in vTv Therapeutics by 51.6% in the first quarter. Millennium Management LLC now owns 95,031 shares of the biotechnology company's stock valued at $387,000 after buying an additional 32,362 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in vTv Therapeutics by 55.9% in the first quarter. JPMorgan Chase & Co. now owns 327,728 shares of the biotechnology company's stock valued at $1,333,000 after buying an additional 117,513 shares during the last quarter. Finally, C WorldWide Group Holding A S purchased a new stake in vTv Therapeutics in the first quarter valued at approximately $399,000. Hedge funds and other institutional investors own 13.42% of the company's stock.
Several research firms recently weighed in on VTVT. Zacks Investment Research upgraded vTv Therapeutics from a "hold" rating to a "buy" rating and set a $1.75 target price for the company in a research note on Thursday, May 24th. ValuEngine upgraded vTv Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. The stock currently has a consensus rating of "Hold" and a consensus price target of $13.11.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease